Jukema JW, Szarek M, Zijlstra LE, et al. - Researchers investigated the impact of polyvascular disease on the risks of major adverse cardiovascular events (MACEs) and mortality and their modification by alirocumab in patients with recent acute coronary syndrome (ACS) and dyslipidemia despite intensive statin therapy in this pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab). Alirocumab or placebo was randomly received by patients 1 to 12 months following ACS. Findings revealed a link of polyvascular disease with high risks of MACEs and death in patients with recent ACS and dyslipidemia despite intensive statin treatment. A potential benefit for these patients was the observed alirocumab-induced large absolute reductions in those risks.